---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-024402"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-11-20T23:59:59+00:00"
generated_at: "2026-05-16T18:12:06.206374+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MAIA starts Romania enrollment for Phase 2 THIO-101 Part C; 38% ORR vs standard 6% cited

## Summary
- CEO presented at Smart Diaspora 2025; Romania begins screening patients for THIO-101 Part C.
- Observed 38% overall response rate vs current third-line NSCLC treatments with ~6% response rate.
- FDA Fast Track Designation for ateganosine received in July 2025, supports accelerated approval path.
- Third-line NSCLC patients resistant to chemo and immunotherapy are target population.
- Investigator Tudor Ciuleanu, MD, PhD, is key opinion leader in Eastern Europe.

## SEC filing metadata
- accession: 0001493152-25-024402
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315225024402/0001493152-25-024402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315225024402/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-024402
- JSON: https://secwatch.observer/filing/0001493152-25-024402.json
- Plain text: https://secwatch.observer/filing/0001493152-25-024402.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.